13.95 -0.20 (-1.41%)
After hours: 6:21PM EST
|Bid||13.70 x 500|
|Ask||14.00 x 100|
|Day's range||13.40 - 14.65|
|52-week range||5.50 - 16.20|
|PE ratio (TTM)||N/A|
|Earnings date||14 Mar 2018 - 19 Mar 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||33.67|
Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced that it intends to offer and sell, subject to market conditions, 3,700,000 shares of its common stock in an underwritten public offering. In addition, Stemline intends to grant the underwriters a 30-day option to purchase up to an additional 555,000 shares of its common stock offered in the public offering. J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering.
NEW YORK, Jan. 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fluidigm Corporation (NASDAQ:FLDM), Stemline Therapeutics, Inc. (NASDAQ:STML), NeoGenomics, Inc. (NASDAQ:NEO), CVR Energy Inc. (NYSE:CVI), W.R. Berkley Corporation (NYSE:WRB), and Mack-Cali Realty Corporation (NYSE:CLI), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Stemline Therapeutics Inc. into potential breaches of fiduciary duty by the Company’s Board of Directors .
NEW YORK, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers announced today that Ivan Bergstein, M.D., Stemline’s CEO, will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 9:30 AM PT (12:30 PM ET) at the Westin St. Francis Hotel in San Francisco, CA. A live webcast of the presentation can be viewed on the company's website at www.stemline.com.
Shares of biotech Stemline Therapeutics Inc. jumped 4% premarket Wednesday, after the company said a trial of a treatment for acute myeloid leukemia met its main goal. Stemline said data from the trial ...
The New York-based company said it had a loss of 68 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a ...